logo

PRPH

ProPhase Labs·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About PRPH

Prophase Labs, Inc.

A growth oriented and diversified diagnostics, genomics and biotech company

Pharmaceutical
--
07/07/1997
NASDAQ Stock Exchange
96
12-31
Common stock
626 RXR Plaza 6th Floor Uniondale New York 11556
--
ProPhase Labs, Inc., was founded in Nevada in 1989. Transferred from Nevada to Delaware on June 18, 2015. The company is a growth-oriented, diversified next-generation biotechnology, genomics and diagnostic company that develops and commercializes new drugs, dietary supplements and compounds, and provides contract manufacturing services.

Earnings Call

Company Financials

EPS

PRPH has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.11, missing expectations. The chart below visualizes how PRPH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRPH has released its 2025 Q3 earnings report, with revenue of 883.00K, reflecting a YoY change of -37.64%, and net profit of -6.84M, showing a YoY change of -3.83%. The Sankey diagram below clearly presents PRPH's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime